Sean Mackay



Sean Mackay

Sean is the CEO of Isoplexis. IsoPlexis is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. IsoPlexis has created a next-generation system, capable of identifying and predicting patient responses to immunotherapy more accurately than conventional assays. Their single-cell multiplexed proteomics platform helps identify the patients most likely to respond to a variety of novel immunotherapies.

Follow Sean Mackay' at upcoming/ongoing conferences at gtcbio:

Immunotherapeutics & Immunomonitoring 2018